Skip to content

The analgesic and antidepressant effects of Xiaoyao San on dry eyes and the effects of IL-6 and IL-1ß in tears

The analgesic and antidepressant effects of Xiaoyao San on dry eyes and the effects of IL-6 and IL-1ß in tears

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005451
Enrollment
Unknown
Registered
2021-12-26
Start date
2021-12-31
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye

Interventions

experimental group:Xiao yao San Pill
experimental group:Diquafosol ophthalmic solution

Sponsors

Jinhua Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Diagnostic criteria for dry eye: Eyes have symptoms such as dryness, foreign body sensation, burning sensation, fatigue, discomfort, vision fluctuations, tear film breakup time (BUT) = 5 seconds, tear secretion test ? (Schirmer ? test) ) =5mm/5min, or BUT between 5-10 seconds, Schirmer ? test 5-10mm/5min and positive staining of corneal and conjunctival fluorescein. Inclusion criteria: age between 20 and 70 years old; able to cooperate with diagnosis and treatment; sign informed consent and participate voluntarily; follow-up for 6 months.

Exclusion criteria

Exclusion criteria: Congenital lacrimation, conjunctivitis, keratitis, uveitis, scleritis, meibomian gland cysts and other eye diseases under treatment; ocular trauma caused by incomplete eyelid structure, eyelid scars, partial eyelid Deformities, etc.; organic diseases such as space-occupying eyes; trauma, hemorrhage, skin infections or skin diseases in the eyes; acute attacks of glaucoma, bleeding in the fundus, etc.; allergies to any component such as drugs; fever, severe heart disease Cerebrovascular diseases, infectious diseases, pregnant women, etc.; patients with diabetes, arthritis, connective tissue disease history, mental illness, cognitive impairment, etc.; patients currently taking antidepressants or anti-anxiety drugs

Design outcomes

Primary

MeasureTime frame
Interleukin-1ß;Interleukin 6;

Contacts

Public ContactQian Lijun
yingzhexuan2012@163.com13757976984

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026